CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Sees Large Decline in Short Interest

CNS Pharmaceuticals, Inc. (NASDAQ:CNSPGet Free Report) was the target of a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 102,600 shares, a drop of 87.2% from the January 31st total of 802,400 shares. Approximately 1.3% of the company’s shares are short sold. Based on an average daily volume of 335,600 shares, the short-interest ratio is currently 0.3 days.

CNS Pharmaceuticals Stock Performance

Shares of CNS Pharmaceuticals stock remained flat at $0.26 during trading on Wednesday. 169,685 shares of the stock traded hands, compared to its average volume of 469,551. CNS Pharmaceuticals has a 12-month low of $0.23 and a 12-month high of $4.40. The company has a 50 day simple moving average of $0.67 and a two-hundred day simple moving average of $1.34.

Institutional Trading of CNS Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Armistice Capital LLC bought a new position in shares of CNS Pharmaceuticals during the 4th quarter worth $155,000. Smith Anglin Financial LLC purchased a new stake in shares of CNS Pharmaceuticals in the 4th quarter worth approximately $64,000. State Street Corp bought a new position in shares of CNS Pharmaceuticals during the second quarter valued at approximately $50,000. Geode Capital Management LLC bought a new position in CNS Pharmaceuticals in the second quarter worth approximately $36,000. Finally, Acadian Asset Management LLC purchased a new stake in CNS Pharmaceuticals during the second quarter worth $49,000. 4.72% of the stock is owned by hedge funds and other institutional investors.

CNS Pharmaceuticals Company Profile

(Get Free Report)

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.

Further Reading

Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.